Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover

v3.24.1.1.u2
Cover
 12 Months Ended
Dec. 31, 2023
shares
Entity Addresses [Line Items]  
Document Type 20-F
Amendment Flag false
Document Registration Statement false
Document Annual Report true
Document Transition Report false
Document Shell Company Report false
Document Period End Date Dec. 31, 2023
Document Fiscal Period Focus FY
Document Fiscal Year Focus 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-40858
Entity Registrant Name XORTX Therapeutics Inc.
Entity Central Index Key 0001729214
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 3710 — 33rd Street NW
Entity Address, City or Town Calgary
Entity Address, State or Province AB
Entity Address, Country CA
Entity Address, Postal Zip Code T2L 2M1
Title of 12(b) Security Common Shares
Trading Symbol XRTX
Security Exchange Name NASDAQ
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Document Accounting Standard International Financial Reporting Standards
Entity Shell Company false
Document Financial Statement Error Correction [Flag] false
Entity Common Stock, Shares Outstanding 1,998,848
Auditor Firm ID 995
Auditor Name Smythe LLP
Auditor Location Vancouver, Canada
Business Contact [Member]  
Entity Addresses [Line Items]  
Entity Address, Address Line One 3710 — 33rd Street NW
Entity Address, City or Town Calgary
Entity Address, State or Province AB
Entity Address, Country CA
Entity Address, Postal Zip Code T2L 2M1
City Area Code 403
Local Phone Number 455-7727
Contact Personnel Name James Fairbairn
Contact Personnel Email Address jfairbairn@xortx.com